[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eating-behavior-changes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eating-behavior-changes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100622759","clinical-and-neurobehavioral-changes-with-weight-loss-drug-discontinuation-and-reinitiation-100622759",false,"NCT07387796","Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation","CLIN-GLP1","Inclusion Criteria:\n\n* Aged 18-70 years.\n* Currently on tirzepatide.\n* Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.\n* Cognitively capable of understanding and signing informed consent.\n* Be proficient in English.\n\nExclusion Criteria:\n\n* History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).\n* Diagnosis of Type 2 Diabetes.\n* Current diagnosis of an eating disorder.\n* Use of medications affecting weight other than tirzepatide.\n* Pregnancy or breastfeeding.\n* MR contraindications:\n* Heart pacemaker, heart valve replacement, or aortic clips\n* Metal fragments in the eyes, skin, or elsewhere in the body\n* Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass\n* Venous umbrella\n* Pieces of metal in the body resulting from work as a sheet-metal worker or welder\n* Clips placed in an internal organ\n* Prosthetic devices, such as middle ear, eye, joint, or penile implants\n* Joint replacement\n* Hearing aid that cannot be removed\n* Neurostimulator\n* Insulin pump\n* Shunts or stents\n* Metal mesh or coil implants\n* Metal plate, pin, screws, or wires, or any other metal implants","ALL","18 Years","70 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide. Specifically, the study aims to examine how a short pause in tirzepatide affects hunger, mood, sleep, and daily functioning; how stopping and restarting tirzepatide alters brain chemistry and brain responses to food-related images; and how these changes relate to health measures such as quality of life and emotional well-being. There is no comparison group; instead, researchers will assess changes within each participant across three time points: while taking tirzepatide, after stopping it for 3-4 weeks, and after restarting it for 6-8 weeks. Participants will attend three in-person visits lasting approximately 3-4 hours each, during which they will complete interviews, questionnaires, and cognitive tasks; provide a urine sample (pregnancy screening for females); undergo a brain scan using magnetic resonance imaging (MRI) and MR spectroscopy (MRS); and receive a kit to provide a small stool sample. Participants will also complete two brief check-in phone calls between visits and the online BrainHealth Index between sessions, which includes surveys and cognitive tasks. All changes to tirzepatide use will occur under the supervision of a study physician to support participant safety and comfort, and the total study duration is approximately 13 weeks.",[28,29,30,31],"Drug Discontinuation","Substance Use Disorders","Eating Behavior Changes","Tirzepatide",[31,28,29,30],"RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":22},"2026-06",{"date":41,"type":22},"2029-02",{"name":43,"class":44},"The University of Texas at Dallas","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100610560","changes-in-taste-and-eating-habits-associated-with-glp-1-agonists-in-weight-loss-patients-100610560","NCT07229170","Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients","Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.","GLP1-TASTE","Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment.\n\nExclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.","60 Years",{"count":56,"type":22},150,"OBSERVATIONAL","This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of GLP-1 agonist treatment. The study's primary goal is to understand how these treatments affect food preferences and taste perception. Secondary outcomes include changes in body weight, body composition, gastrointestinal side effects, and treatment adherence. All data are anonymized and collected according to ethical guidelines.",[60,61,62,30],"Obesity & Overweight","Taste Alterations","Weight Loss",[64,65,66,67,68,69],"GLP-1 agonists","Obesity treatment","Weight loss","Taste perception","Eating habits","Observational study","2026-04-22",{"date":72,"type":37},"2026-04-28",{"date":74,"type":37},"2025-12-01",{"date":76,"type":22},"2028-01-01",{"name":78,"class":44},"San Raffaele Telematic University",4,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100630624","adaptation-strategies-for-coping-with-the-impact-of-sensory-alterations-on-eating-behavior-in-children-with-cancer-a-qualitative-study-from-the-perspective-of-children-and-parents-100630624","NCT07490093","Adaptation Strategies for Coping With the Impact of Sensory Alterations on Eating Behavior in Children With Cancer: A Qualitative Study From the Perspective of Children and Parents","QUALISENS","Inclusion Criteria:\n\nChildren:\n\n* Aged 6 to 17 years old on the day consent is obtained.\n* Diagnosed with a malignant hematological or oncological tumor.\n* Possessing sufficient verbal ability to participate in the interview planned for the study.\n* Having started chemotherapy treatment at least 2 months prior.\n* Agreeing to participate in the study.\n* Able to understand, read, and write French.\n* Affiliated with a social security system.\n\nParents:\n\n* Be the parent or legal guardian of a child aged 6 to 17 inclusive, with cancer and undergoing chemotherapy.\n* Dated and signed informed consent.\n* Able to understand, read, and write French.\n\nExclusion Criteria:\n\n\\-","6 Years","17 Years",{"count":90,"type":22},30,"Childhood cancer is a serious and life-changing disease that affects thousands of children every year worldwide. In addition to the disease itself, cancer treatments such as chemotherapy often cause difficult side effects. Among these, changes in taste and smell are very common but still poorly understood in children. These sensory changes can make food taste unpleasant or smell different, leading children to eat less, avoid certain foods, or develop strong food aversions. As a result, many children with cancer experience weight loss, poor nutrition, and reduced quality of life, which can also affect how well they tolerate treatment.\n\nResearch suggests that between 40% and 60% of children with cancer struggle to maintain good nutritional status during treatment. Taste and smell alterations play a major role in these difficulties. Children may experience nausea triggered by food smells, changes in food texture perception, or a loss of pleasure in eating. Parents often report feeling powerless and lacking clear guidance on how to help their child cope with these problems.\n\nWhile taste and smell disturbances have been widely studied in adults with cancer, much less is known about how children experience these changes and, importantly, how they and their families adapt to them. Parents play a key role in supporting their child's eating habits, but their perspectives may differ from the child's own experiences.\n\nThis study aims to better understand how children undergoing chemotherapy and their parents perceive changes in taste, smell, and food texture, and how these changes affect eating behavior, emotions, and social life. Using individual semi-structured interviews, the study will explore the coping strategies used by children and parents to manage these sensory changes, both at home and in the hospital setting.\n\nBy giving children and parents a voice, this research seeks to identify practical, real-life strategies that families find helpful. The results will contribute to improving nutritional support and guidance for children with cancer, with the ultimate goal of enhancing their well-being, quality of life, and treatment outcomes.",[61,93,30],"Smell Disorder",[95,96,97,98,99,100,101],"chemotherapy","oncology","children","taste alterations","smell disorder","eating behaviour changes","coping strategies","NOT_YET_RECRUITING","2026-03-19",{"date":105,"type":37},"2026-03-24",{"date":107,"type":22},"2026-02",{"date":109,"type":22},"2026-10",{"name":111,"class":44},"Centre Leon Berard"]